GlassScriptPhysician profile
Varun Chawla
NPI 1609067537
$92,459.65
in general payments reported to CMS, 2019-2025
36 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $6,155 · 2021: $16K · 2022: $23K · 2023: $5,767 · 2024: $3,871 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $6,152 · Travel and Lodging: $2,805 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,676 · Education: $543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,249.26 |
| Food and Beverage | $6,151.83 |
| Travel and Lodging | $2,804.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,676.00 |
| Education | $542.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $20,493.04 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $18,785.80 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $15,159.61 | 2019-2024 | Veltassa, Korsuva |
| Amgen INC. | $12,053.84 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Novartis Pharmaceuticals Corporation | $8,469.32 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,553.49 | 2020-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $4,516.26 | 2022-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $1,327.55 | 2019-2025 | Filspari |
| Fresenius USA Marketing, INC. | $424.22 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Opko Pharmaceuticals, LLC | $371.42 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $360.76 | 2020-2025 | Benlysta, Jesduvroq |
| Novo Nordisk INC | $333.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $330.36 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $316.56 | 2019-2025 | Jynarque |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.70 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $189.58 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.78 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $166.04 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $150.36 | 2023-2025 | Ibsrela |
| Baxter Healthcare | $135.72 | 2019 | |
| Bard Peripheral Vascular, INC. | $135.28 | 2019 | |
| Genzyme Corporation | $111.88 | 2019-2023 | |
| Akebia Therapeutics INC | $109.39 | 2020 | |
| Daiichi Sankyo INC. | $105.51 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $79.86 | 2024-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $79.82 | 2019-2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $50.38 | 2020-2024 | Xarelto |
| Ani Pharmaceuticals, INC. | $43.03 | 2023-2025 | Purified Cortrophin Gel |
| Ultragenyx Pharmaceutical INC. | $41.67 | 2023-2024 | Crysvita |
| Apellis Pharmaceuticals, INC. | $36.26 | 2025 | Empaveli |
| Veloxis Pharmaceuticals, INC. | $35.98 | 2024-2025 | Envarsus |
| Genentech USA, INC. | $29.78 | 2025 | Gazyva |
| Mallinckrodt Enterprises LLC | $21.20 | 2019 | |
| Scpharmaceuticals INC. | $18.51 | 2025 | |
| Kyowa Kirin, INC. | $14.55 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.